Literature DB >> 25343110

The current clinical aspects of idiopathic portal hypertension.

Tomohiro Tanaka1, Yasuhiko Sugawara2, Norihiro Kokudo2.   

Abstract

IDIOPATHIC PORTAL HYPERTENSION (IPH) COMPRISES DISORDERS DEVELOPING INCREASED PORTAL PRESSURE IN THE ABSENCE OF CIRRHOSIS: the clear mechanisms to explain this disease are still not well recognized. IPH usually suggests a benign prognosis, but sometimes is complicated with severe hemorrhage due to ruptured esophageal varices, or massive splenomegaly. Conventional treatments for those complications for patients with cirrhosis usually works when diverted to patients with IPH, although some of those patients might require liver transplantation if the treatment fails. However, there are few consistent treatment strategies for IPH itself, its complications or the indications for liver transplantation. In this mini review, we summarize the clinical manifestations and several potential theories to explain the etiology, as well as the current treatment options for IPH.

Entities:  

Keywords:  Idiopathic noncirrhotic portal hypertension; Idiopathic portal hypertension (IPH); nodular regenerative hyperplasia (NRH); non-cirrhotic portal fibrosis

Year:  2013        PMID: 25343110      PMCID: PMC4204548          DOI: 10.5582/irdr.2013.v2.3.94

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  42 in total

1.  Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients.

Authors:  Shiv K Sarin; Manav Wadhawan; Rajesh Gupta; Hansa Shahi
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

2.  A familial form of incomplete septal cirrhosis.

Authors:  J L Barnett; H D Appelman; R H Moseley
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

Review 3.  Portal hypertension and its complications.

Authors:  Arun J Sanyal; Jaime Bosch; Andres Blei; Vincente Arroyo
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

4.  Familial aggregation in noncirrhotic portal fibrosis: a report of four families.

Authors:  S K Sarin; N K Mehra; A Agarwal; V Malhotra; B S Anand; V Taneja
Journal:  Am J Gastroenterol       Date:  1987-11       Impact factor: 10.864

5.  Analysis of adhesion molecules in patients with idiopathic portal hypertension.

Authors:  N Yamaguchi; K Tokushige; I Haruta; K Yamauchi; N Hayashi
Journal:  J Gastroenterol Hepatol       Date:  1999-04       Impact factor: 4.029

6.  Adams-Oliver syndrome and hepatoportal sclerosis: occasional association or common mechanism?

Authors:  Muriel Girard; Jeanne Amiel; Monique Fabre; Danièle Pariente; Stanislas Lyonnet; Emmanuel Jacquemin
Journal:  Am J Med Genet A       Date:  2005-06-01       Impact factor: 2.802

7.  Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population.

Authors:  P Schwärzler; J S Carvalho; M V Senat; T Masroor; S Campbell; Y Ville
Journal:  Br J Obstet Gynaecol       Date:  1999-10

8.  Idiopathic portal hypertension; a histopathological study of 26 Japanese cases.

Authors:  J Ludwig; E Hashimoto; H Obata; W P Baldus
Journal:  Histopathology       Date:  1993-03       Impact factor: 5.087

9.  Vascular involvement of the liver in Turner's syndrome.

Authors:  Dominique Roulot; Claude Degott; Olivier Chazouillères; Frédéric Oberti; Paul Calès; Nicolas Carbonell; Said Benferhat; Solange Bresson-Hadni; Dominique Valla
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

10.  Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients.

Authors:  S Hillaire; E Bonte; M-H Denninger; N Casadevall; J-F Cadranel; D Lebrec; D Valla; C Degott
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

View more
  6 in total

1.  Idiopathic portal hypertension presenting with hepatic nodular regenerative hyperplasia after splenectomy: a case report.

Authors:  Yan Ren; Hui Liu; Wen-Yan Song; Ai-Qin Hao; Lu Li; Shuang Liu; Yu Chen; Zhong-Ping Duan; Su-Jun Zheng
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

2.  A case of idiopathic portal hypertension accompanying multiple hepatic nodular regenerative hyperplasia in a patient with systemic sclerosis.

Authors:  Arisa Yamamoto; Hidetaka Matsuda; Katsushi Hiramatsu; Arisa Tsuji; Yohei Midori; Yosuke Murata; Tomoko Tanaka; Gen Tohda; Takuto Nosaka; Kazuto Takahashi; Tatsushi Naito; Kazuya Ofuji; Masahiro Ohtani; Yoshiaki Imamura; Yasunari Nakamoto
Journal:  Clin J Gastroenterol       Date:  2021-04-22

3.  Splenic Marginal Zone Lymphoma in the Setting of Noncirrhotic Portal Hypertension.

Authors:  Saman Ratnayake; Ali Ammar; Rodd Rezvani; Greti Petersen
Journal:  J Investig Med High Impact Case Rep       Date:  2015-09-30

4.  Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension.

Authors:  Sabine Klein; Christian Hinüber; Kanishka Hittatiya; Robert Schierwagen; Frank Erhard Uschner; Christian P Strassburg; Hans-Peter Fischer; Ulrich Spengler; Jonel Trebicka
Journal:  PLoS One       Date:  2016-09-02       Impact factor: 3.240

5.  Outcomes of partial splenic embolization in patients with massive splenomegaly due to idiopathic portal hypertension.

Authors:  Omer Ozturk; Gonca Eldem; Bora Peynircioglu; Taylan Kav; Aysegul Görmez; Barbaros Erhan Cil; Ferhun Balkancı; Cenk Sokmensuer; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2016-11-21       Impact factor: 5.742

Review 6.  Living donor liver transplantation for idiopathic portal hypertension with extrahepatic portal vein stenosis and splenic artery aneurysms: a case report and review of the literature.

Authors:  Shigeyuki Kawachi; Naokazu Chiba; Masashi Nakagawa; Toshimichi Kobayashi; Kosuke Hikita; Toru Sano; Koichi Tomita; Hiroshi Hirano; Yuta Abe; Hideaki Obara; Motohide Shimazu
Journal:  BMC Surg       Date:  2020-10-29       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.